Presentation is loading. Please wait.

Presentation is loading. Please wait.

Lapatinib cooperates with PLX4032 to inhibit BRAF-mutant thyroid cancer cell growth. Lapatinib cooperates with PLX4032 to inhibit BRAF-mutant thyroid cancer.

Published byMarilyn Fisher Modified over 5 years ago

Similar presentations

Presentation on theme: "Lapatinib cooperates with PLX4032 to inhibit BRAF-mutant thyroid cancer cell growth. Lapatinib cooperates with PLX4032 to inhibit BRAF-mutant thyroid cancer."— Presentation transcript:

1 Lapatinib cooperates with PLX4032 to inhibit BRAF-mutant thyroid cancer cell growth.
Lapatinib cooperates with PLX4032 to inhibit BRAF-mutant thyroid cancer cell growth. A, bars represent growth inhibition of 8505C, SW1736, and Hth104 cells by lapatinib, PLX4032, or their combination. Growth was measured 4 days after addition of the indicated concentration of PLX4032 in the absence or presence of 1 μmol/L lapatinib, or after addition of the indicated concentration of lapatinib in the absence or presence of 2 μmol/L PLX4032. Bars represent percent change (mean ± SD) in cell count of triplicate wells compared with untreated cells. B, SW1736 and 8505 cells were treated with 2 μmol/L PLX4032, 0.1 μmol/L AZD6244, or 1 μmol/L lapatinib alone or in combination for 48 hours. FACS shows a significant increase in G1 phase in cells exposed to PLX4032 or AZD6244 when combined with lapatinib. C, thyroid volumes of TPO-Cre/LSL-BrafV600E mice treated with lapatinib (150 mg/kg 5 times a week), PLX4720-impregnated chow, or their combination at days 0 and 21 of treatment. The fold-change of thyroid volume was significantly lower in mice treated with the combination compared with vehicle (P = 0.02), and PLX4720 alone (P = 0.02). D, bars represent average number of Ki67-positive cells per high-power field in mice treated as described above for 2 weeks, except that lapatinib was given 3 times a week alone or in combination with PLX4720. At least 8 higher-powered fields/section on 4 separate sections were counted for each mouse (2–3 mice per treatment group). **, P < 0.01. Cristina Montero-Conde et al. Cancer Discovery 2013;3: ©2013 by American Association for Cancer Research

Download ppt "Lapatinib cooperates with PLX4032 to inhibit BRAF-mutant thyroid cancer cell growth. Lapatinib cooperates with PLX4032 to inhibit BRAF-mutant thyroid cancer."

Similar presentations

Supplementary Figure 1 Sensitive Resistant Cell Count Propidium Iodide

Supplementary Figure 1 Sensitive Resistant Cell Count Propidium Iodide
Fig. 1. ER binding assays. (A) Mouse ER

Fig. 1. ER binding assays. (A) Mouse ER
Drug concentration (μM)

Drug concentration (μM)
DNA content flow cytometric histograms of propidium iodide–stained A549 cells. DNA content flow cytometric histograms of propidium iodide–stained A549.

DNA content flow cytometric histograms of propidium iodide–stained A549 cells. DNA content flow cytometric histograms of propidium iodide–stained A549.
SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.
Inhibition of FGFR fusion kinase activity repressed tumor growth in a mouse xenograft model. Inhibition of FGFR fusion kinase activity repressed tumor.

Inhibition of FGFR fusion kinase activity repressed tumor growth in a mouse xenograft model. Inhibition of FGFR fusion kinase activity repressed tumor.
HER2 mutations V777L, D769H, V842I, G309A induce gain-of-function over HER2 WT in MCF10A mammary epithelial cells. HER2 mutations V777L, D769H, V842I,

HER2 mutations V777L, D769H, V842I, G309A induce gain-of-function over HER2 WT in MCF10A mammary epithelial cells. HER2 mutations V777L, D769H, V842I,
Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.

Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.
CDK4 is required for the hormone-independent growth of ER+ breast cancer cells. CDK4 is required for the hormone-independent growth of ER+ breast cancer.

CDK4 is required for the hormone-independent growth of ER+ breast cancer cells. CDK4 is required for the hormone-independent growth of ER+ breast cancer.
Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.

Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.
Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.
Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.

Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.
Volume 19, Issue 3, Pages (March 2017)

Volume 19, Issue 3, Pages (March 2017)
DQ661 improves survival in colon cancer model and potentiates activity of gemcitabine in KPC pancreatic cancer syngeneic model. DQ661 improves survival.

DQ661 improves survival in colon cancer model and potentiates activity of gemcitabine in KPC pancreatic cancer syngeneic model. DQ661 improves survival.
Level of EGFR inhibition determines cell death response in EGFR mutant GBM cells. Level of EGFR inhibition determines cell death response in EGFR mutant.

Level of EGFR inhibition determines cell death response in EGFR mutant GBM cells. Level of EGFR inhibition determines cell death response in EGFR mutant.
The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma cells. The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma.

The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma cells. The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma.
Merlin-deficient RAS-mutant cells and murine PDTCs are more sensitive to MEK inhibition. Merlin-deficient RAS-mutant cells and murine PDTCs are more sensitive.

Merlin-deficient RAS-mutant cells and murine PDTCs are more sensitive to MEK inhibition. Merlin-deficient RAS-mutant cells and murine PDTCs are more sensitive.
Cytotoxic therapy induces CSF1-dependent macrophage recruitment.

Cytotoxic therapy induces CSF1-dependent macrophage recruitment.
A, left: indicated MEFs were transfected as described in the Methods section. A, left: indicated MEFs were transfected as described in the Methods section.

A, left: indicated MEFs were transfected as described in the Methods section. A, left: indicated MEFs were transfected as described in the Methods section.
Imipramine and promethazine induce the apoptotic cell death of SCLC cells through activation of caspase-3. Imipramine and promethazine induce the apoptotic.

Imipramine and promethazine induce the apoptotic cell death of SCLC cells through activation of caspase-3. Imipramine and promethazine induce the apoptotic.

Similar presentations

Ads by Google